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Abstract	Several	lines	of	evidence	are	indicative	of	a	role	for	immune	activation	in	the	pathophysiology	of	schizophrenia.	Nevertheless,	studies	using	Positron	Emission	Tomography	(PET)	and	radioligands	for	the	translocator	protein	(TSPO),	a	marker	for	glial	activation,	have	yielded	inconsistent	results.	Whereas	early	studies	using	a	radioligand	with	low	signal	to	noise	in	small	samples	showed	increases	in	patients,	more	recent	studies	with	improved	methodology	has	shown	no	differences	or	trend-level	decreases.	Importantly,	all	patients	investigated	thus	far	have	been	on	antipsychotic	medication,	and	since	these	compounds	may	dampen	immune	cell	activity,	this	factor	limits	the	conclusions	that	can	be	drawn.	Here,	we	examined	16	drug-naϊve,	first	episode	psychosis	patients	and	16	healthy	controls	using	PET	and	the	TSPO	radioligand	[11C]PBR28.	Gray	matter	(GM)	Volume	of	Distribution	(VT)	derived	from	a	two-tissue	compartmental	analysis	with	arterial	input	function	was	the	main	outcome	measure.	Statistical	analyses	were	performed	controlling	for	both	TSPO	genotype,	which	is	known	to	affect	[11C]PBR28	binding,	and	gender.	There	was	a	significant	reduction	of	[11C]PBR28	VT	in	patients	compared	to	healthy	controls	in	GM	as	well	as	in	secondary	regions	of	interest.	No	correlation	was	observed	between	GM	VT	and	clinical	or	cognitive	measures	after	correction	for	multiple	comparisons.	The	observed	decrease	in	TSPO	binding	suggests	reduced	numbers	or	altered	function	of	immune	cells	in	brain	in	early	stage	schizophrenia.		
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Introduction	Schizophrenia	is	a	severe	mental	disorder	for	which	currently	available	treatment	is	satisfactory	only	in	a	minority	of	cases.	Cognitive	impairment,	such	as	memory	dysfunction	and	reduced	speed	of	processing,	are	present	already	at	an	early	stage	of	the	disease,	and	are	particularly	difficult	to	ameliorate1.	The	development	of	new,	improved	treatment	approaches	is	presently	hampered	by	a	lack	of	understanding	of	the	pathophysiology	of	the	disease.				Genetic	and	epidemiological	data	are	indicative	of	an	involvement	of	the	immune	system	in	the	development	of	schizophrenia2,3.	In	patients,	an	on-going	immune	activation	is	suggested	by	studies	showing	elevation	of	immune	markers	in	blood	and	CSF	both	during	long-term	illness,	as	well	as	in	first	episode	psychosis	4–7.	Using	Positron	Emission	Tomography	(PET)	and	radioligands	for	the	translocator	protein	18kDA	(TSPO),	which	in	brain	is	expressed	primarily	in	microglia	and	astrocytes,	it	is	possible	to	index	brain	immune	cell	activation	in	
vivo	8–10.	Initial	TSPO	PET	studies	in	small	samples	have	shown	increased	binding	in	patients	with	schizophrenia	as	compared	to	controls11,12,		however	a	radioligand	with	low	signal-to-noise	ratio	was	used,	as	well	as	an	outcome	measure	generally	shown	to	be	less	reliable	13.	More	recent	studies	using	novel	TSPO	radioligands	have	failed	to	replicate	these	findings.		Although	increases	in	a	relative	measure	of	binding	was	recently	reported	in	schizophrenia	patients	and	ultra-high-risk	individuals,	there	was	no	absolute	TSPO	elevation	using	standard	methods	of	quantification14.	This	observation	is	in	line	with	results	from	other	studies	in	patients	with	long-term	illness15,16,	as	well	as	a	recent	study	in	patients	with	recent-onset	disease	where	a	trend-level	reduction	in	TSPO	was	observed17.	
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	A	major	limitation	of	the	studies	published	thus	far	is	that	all	patients	have	been	on	treatment	with	antipsychotic	medication.	Importantly,	several	of	these	compounds	have	shown	to	attenuate	blood	cytokine	levels	in	patients18	as	well	as	decrease	binding	to	TSPO	in	preclinical	studies19.	Though	the	high-risk	individuals	investigated	by	Bloomfield	et	al14	were	unexposed	to	antipsychotic	medication,	on	average	less	than	30%	of	this	group	go	on	to	develop	a	psychotic	disorder20,	indicating	that	the	group	is	heterogeneous	and	cannot	be	equated	with	a	prodromal	phase	of	schizophrenia.			The	aim	of	the	present	study	was	to	overcome	the	critical	drawback	of	previous	investigations	by	measuring	TSPO	binding	in	antipsychotic-naϊve,	first	episode	psychotic	patients,	as	compared	to	age-matched	control	subjects.			
Subjects	and	methods	
Patients	and	control	subjects	The	study	was	approved	by	the	Regional	Ethics	Committee	in	Stockholm	and	the	Radiation	Safety	Committee	at	the	Karolinska	University	Hospital,	Stockholm.	Subjects	were	included	after	providing	written	informed	consent	after	receiving	a	complete	description	of	the	study.		Sixteen	first-episode	psychotic	patients	(11	male,	5	female,	mean	age	26.4	(SD	8.4))	were	recruited	from	psychiatric	emergency	wards	and	out-patient	clinics	in	Stockholm.	At	time	of	investigation	all	patients	were	naïve	to	antipsychotic	
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treatment	and	met	the	diagnostic	criteria	for	Schizophrenia	(n=3),	Schizophreniform	Psychosis	(n=4),	Psychosis	NOS	(n=7)	or	Brief	Psychosis	(n=2),	according	to	DSM-IV.	Exclusion	criteria	were	neurologic	or	severe	somatic	illness,	current	use	or	history	of	abuse	of	illegal	drugs	(including	cannabis)	and	autism-spectrum	disorder.	Absence	of	major	brain	abnormalities	was	confirmed	using	Magnetic	Resonance	Imaging	(MRI).	Occasional	medication	with	sedatives	and	anxiolytics,	including	benzodiazepines	(BZ),	were	allowed	during	the	course	of	the	study,	as	well	as	medication	with	antidepressants.	In	cases	where	diazepam	was	used,	the	daily	dose	was	significantly	lower	than	equivalent	concentrations	of	this	drug	shown	to	affect	TSPO	binding	according	to	in	vitro	data21.				Sixteen	control	subjects	(7	male,	9	female,	age	28.5	(8.4))	were	recruited	by	advertisement.	They	were	healthy	according	to	medical	history,	clinical	examination,	routine	laboratory	blood	and	urine	tests	as	well	as	a	brain	MRI	examination.	The	Mini	International	Neuropsychiatric	Interview	(MINI)	was	used	to	exclude	previous	or	current	psychiatric	illness.	Further	exclusion	criteria	were	previous	or	current	use	of	illegal	drugs	and	first-degree	relatives	with	psychotic	illness.	None	of	the	control	subjects	were	on	any	medication	at	time	of	the	study.		TSPO	genotype	was	assessed	in	all	subjects	as	described	previously22	using	DNA	extracted	either	from	whole	blood	or	saliva.	There	were	8	High	Affinity	binders	(HABs)	and	8	Mixed	Affinity	Binders	(MABs)	among	the	patients	and	9	HABs	and	7	MABs	in	the	control	group	(Table	1).			
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Behavioral	measures	In	patients,	psychotic	symptoms	were	assessed	using	the	Positive	and	Negative	Syndrome	Scale	for	Schizophrenia	(PANSS)	and	the	Clinical	Global	Impression	(CGI-S)	scale.	Cognitive	functioning	was	assessed	in	all	subjects	using	tests	from	the	Measurement	and	Treatment	Research	to	Improve	Cognition	in	Schizophrenia	(MATRICS)	Consensus	Cognitive	Battery	(MCCB)23,24,	which	is		designed	specifically	to	measure	cognition	in	research	on	schizophrenia1.	The	cognitive	domains	assessed	were	speed	of	processing (using	the	tests Category	Fluency:	Animal	Naming,	Trail	Making	Test:	Part	A	(TMT	A)),	attention/vigilance	(Continuous	Performance	Test-	Identical	Pairs	(CPT-IP),	working	memory	(Wechsler	Memory	Scale	(WMS)®-III:	Spatial	Span),	verbal	learning	(Hopkins	Verbal	Learning	Test	-	Revised	(HVLT-R))	and	visual	learning	(Brief	Visuospatial	Memory	Test	Revised	(BVMT-R)). We	also	performed	the	Wisconsin	Card	Sorting	Test	(WCST)	and	included	categories	completed	and	percent	errors	as	outcome	measures.	
Magnetic	Resonance	Imaging	Brain	MRI	was	performed	at	the	MR	Centre,	Karolinska	University	Hospital,	using	a	3-T	General	Electric	Discovery	MR750	system	(GE,	Milwaukee,	WI).	T2-weighted	images	were	acquired	for	evaluation	regarding	pathology	by	a	neuroradiologist,	and	T1-weighted	images	were	acquired	for	definition	of	regions	of	interest	(ROIs).	
Positron	emission	tomography	procedures		PET	measurements	were	performed	at	the	PET	Centre	at	
	8		
Karolinska	University	Hospital,	Stockholm,	using	a	High	Resolution	Research	Tomograph	(HRRT,	Siemens	Molecular	Imaging,	Knoxville,	TN,	USA).	Individualized	plastic	helmets	were	made	for	each	subject	and	used	together	with	a	head	fixation	system	to	minimize	movement	artifacts.	A	6-min	transmission	scan	using	a	137Cs	source	was	performed	for	attenuation	correction.	[11C]PBR28	was	prepared	as	described	previously25	and	injected	as	a	bolus	over	approximately	10	s	into	the	cubital	vein.	Emission	data	was	acquired	in	list	mode	for	up	to	91	min,	except	for	one	patient	(85	min)	and	two	control	subjects	(77	min).	The	inclusion	of	data	from	these	subjects	were	supported	by	analyses	of	a	previous	dataset22	where	63	minute	2TCM	for	GM	showed	high	correlation	to	that	of	91	minutes	(n=12,	r=0.997,	p=8x10-13).	PET	images	were	reconstructed	using	ordered	subset	expectation	maximization	with	modeling	of	the	point-spread	function,	and	subsequently	corrected	for	head	movement	using	a	frame-by-frame	realignment	process	as	described	previously26,27.		An	automated	blood	sampling	system	(ABSS,	Allogg	AB,	Mariefred,	Sweden)	was	used	during	the	first	5	min	of	each	PET	measurement.	Discrete	arterial	blood	samples	(2–4	mL)	were	drawn	manually	at	1,	3,	5,	7,	9,	10.5,	20,	30,	40,	50,	60,	70,	80	and	90	min,	except	for	one	patient,	for	which	the	samples	were	drawn	at	1,	2,	3,	4,	5,	6,	7,	8,	9,	10.5,	20,	30,	40,	50,	60,	70,	80	and	90	min,	and	two	control	subjects	with	sampling	times	of	2,	4,	6,	8,	10,	15,	20,	25,	30,	40,	50,	60	and	72	min.	The	radioactivity	was	measured	immediately	after	sampling	in	a	well	counter	cross-calibrated	with	the	PET	system.	After	centrifugation,	0.7–1.5	mL	plasma	was	pipetted	and	the	radioactivity	was	measured	in	the	same	well	counter.	The	Area	Under	the	Curve	(AUC)	of	the	standardized	uptake	value	(SUV)	
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for	the	metabolite-corrected	plasma	curves	were	calculated	for	all	subjects	from	0	to	72	minutes.				The	plasma	radioactivity	curve	for	the	first	5	minutes	was	generated	by	combining	the	ABSS	data	with	an	interpolated	curve	from	the	manual	samples,	and	then	multiplied	with	the	blood-to-plasma	ratio	obtained	from	the	plasma	samples	to	create	an	arterial	plasma	curve.	The	time	curve	for	parent	fraction	of	the	radioligand	was	determined	using	HPLC,	fitted	using	a	three-exponential	model	and	multiplied	with	the	plasma	curve	to	generate	the	arterial	input	function.	To	assess	the	impact	of	protein	binding,	the	free	fraction	of	radioligand	was	analyzed	using	an	ultrafiltration	method.	For	additional	details	on	these	procedures	see25,28.	
Quantification	of	[11C]PBR28	binding	MR	images	were	realigned,	segmented	and	coregistered	to	PET	images	using	SPM5	in	MATLAB	R2007b	(Wellcome	Trust	Centre	for	Neuroimaging,	London,	UK;	The	Mathworks,	Natick,	MA)25.	Region	of	interests	(ROIs)	were	defined	using	an	automated	procedure	based	on	the	FreeSurfer	software	(version 5.0.0, 
http://surfer.nmr.mgh.harvard.edu/),	previously	validated	for	PET	data	analysis29.	Gray	matter	(GM)	was	selected	as	the	primary	ROI.	In	addition,	we	examined	white	matter	(WM),	frontal	cortex	(FC),	temporal	cortex	(TC)	and	hippocampus	on	account	of	their	central	interest	for	research	in	schizophrenia	as	well	as	to	enable	comparison	to	previous	TSPO	PET	studies12,14.	Furthermore,	a	FreeSurfer	whole	brain	(WB)	ROI	was	created	for	calculation	of	Distribution	Volume	Ratios	(DVRs),	as	described	previously14.	Volumetric	data	for	all	ROIs	used	in	the	PET	
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analysis	were	extracted	from	FreeSurfer,	as	well	as	for	the	total	intracranial	volume	(ICV).				The	main	outcome	measure	of	TSPO	binding	was	calculated	using	the	two-tissue	compartment	model	(2TCM)	with	a	metabolite-corrected	arterial	plasma	curve	as	input	function.	Binding	was	expressed	as	the	total	volume	of	distribution	(VT),	which	corresponds	to	the	ratio	between	the	sum	of	specific	and	non-displaceable	concentrations	of	radioligand	in	the	target	region	to	the	concentration	in	plasma	at	equilibrium.	As	a	secondary	analysis	to	allow	for	comparison	with	Bloomfield	et	al14,	data	were	analyzed	using	the	2TCM-1K	model	which	includes	an		additional	irreversible	compartment	hypothesized	to	account	for	endothelial	binding		in	blood	vessels30.	All	kinetic	analyses	were	performed	using	MATLAB	R2007b.	Finally,	DVRs	were	calculated	as	the	ratio	between	GM	VT	and	WB	VT	for	both	2TCM	and	2TCM-1K,	to	enable	additional	comparisons	with	previously	published	data14,17.		
Statistics	Normality	of	all	demographic	data,	clinical	and	cognitive	variables,	radiochemical	data	and	uptake	outcome	measures	were	evaluated	using	Kolmogorov-Smirnov	tests	as	well	as	ocular	inspection	of	histograms.	Independent-sample	two-tailed	t-tests	were	performed	to	examine	potential	group	differences	in	demographic	data,	measurements	of	cognitive	function,	radiochemical	data,	ROI	volumes,	free	fraction	of	radioligand	in	plasma	as	well	as	differences	in	plasma	SUV	AUC	values.	For	variables	that	were	not	normally	
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distributed,	a	Mann-Whitney	U	test	was	performed	to	examine	group	differences.	Group	differences	in	categorical	variables	were	assessed	using	a	Chi-square	test.			Effects	of	genotype,	age	and	sex	on	GM	VT	were	examined	using	Pearson’s	correlation	and	independent	sample	t-tests	(two-tailed).	Multivariate	ANCOVA	with	all	ROIs	as	dependent	variables	was	deemed	invalid	because	of	high	multicollinearity	between	the	outcome	measures.	For	the	main	statistical	analysis,	the	difference	between	patients	and	controls	in	[11C]PBR28	binding	in	GM	was	therefore	examined	using	a	univariate	ANCOVA:	GM	VT	derived	from	the	standard	2TCM	model	was	used	as	dependent	variable,	group	(patients	vs.	control	subjects)	as	independent	variable	and	gender	and	genotype	as	covariates.		An	analysis	was	also	performed	excluding	the	5	patients	on	benzodiazepine	treatment.	Furthermore,	effect	sizes	for	GM	binding	was	estimated	for	MABs	and	HABs	separately,	using	partial	eta	squared	values	obtained	from	ANCOVA	analyses	with	gender	as	covariate.		Secondary,	to	examine	group	differences	in	binding	in	FC,	TC,	hippocampus	and	WM,	we	performed	four	additional	univariate	ANCOVAs,	each	having	sex	and	genotype	as	covariates.	To	allow	for	comparison	with	previously	published	results,	the	same	set	of	univariate	ANCOVAs	were	performed	using	regional	VT-values	derived	from	2TCM-1K,	as	well	as	DVR-values	based	on	both	2TCM	and	2TCM-1K	methods	as	dependent	variables14	.	For	the	main	analysis	of	GM	VT	differences,	alpha	was	set	to	0.05.			
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The	relationships	between	GM	VT	and	symptom	levels	(PANSS),	global	functioning	(CGI)	and	duration	of	illness	were	assessed	using	partial	correlation	controlling	for	genotype	and	gender.	For	correlations	between	GM	VT	and	cognitive	measures,	age	was	added	as	a	covariate	and	the	threshold	for	significance	was	Bonferroni-corrected	for	multiple	comparisons	(alpha=0.05/8=0.00625).		All	statistical	analyses	were	performed	in	SPSS	23	(IBM,	Armonk,	N.Y.)	or	R	(version	3.2.4	“Very	Secure	Dishes”).	
	
Results	Patient	and	control	groups	did	not	differ	significantly	in	age,	sex	distribution,	BMI	or	genotype	distribution	(Table	1).	Duration	of	illness	was	7.9	(9.6)	months	and	total	PANSS	score	77.4	(18.3).		None	of	the	patients	had	been	exposed	to	antipsychotic	medication	at	time	of	investigation.	Nine	patients	received	anxiolytics	or	sedatives,	of	which	five	patients	received	benzodiazepines;	(diazepam	(5	mg/day)	in	one	case	and	oxazepam	(10-30	mg/d)	in	four	cases)	(suppl	Table	1).	One	patient	was	prescribed	paroxetin	20	mg/d.	Two	of	the	patients	and	none	of	the	controls	were	cigarette	smokers.	Regional	brain	volumes	did	not	differ	significantly	between	patients	and	controls	(Table	2)	also	after	normalizing	with	ICV	(ST2),	therefore	correction	for	partial	volume	effects	was	not	performed	for	analyses	of	[11C]PBR28	binding.		
Group	effects	on	regional	[11C]PBR28	binding	There	was	a	significant	effect	of	both	genotype	and	sex	on	GM	VT	(t=3.5,	df=30,	p=0.001	and	t=2.1,	df=30,	p=0.043	respectively)	whereas	no	correlation	was	
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observed	between	age	and	GM	VT	(r=-0.09,	p	=0.62).	Hence,	only	sex	and	genotype	was	included	as	covariates	in	the	ANCOVA.	A	decrease	in	[11C]PBR28	GM	VT	was	observed	in	patients	as	compared	to	controls,	with	a	significant	effect	of	group	obtained	in	the	ANCOVA	analysis	(F=6.19,	df=1,28,	p=0.019).	The	decrease	was	more	prominent	in	HAB	patients,	with	an	effect	size	of	0.38	(partial	eta	square)	compared	to	0.02	for	the	MAB	subgroup	(Figure	1).	The	effect	remained	when	excluding	the	5	patients	on	benzodiazepine	treatment	(F=6.71,	df=1,23,	p=0.016).	In	the	regional	analysis,	significant	group	effects	were	observed	for	FC	(F=6.08,	df=1,28,	p=0.020),	TC	(F=6.51,	df=1,28,	p=0.016)	and	hippocampus	(F=5.49	,	df=1,28,	p=0.026	),	but	not	for	WM	(F=1.54,	df=1,28,	p=0.23)	(ST3).	There	was	also	a	significant	effect	of	group	for	GM	VT	derived	using	2TCM-1k	(F=6.66,	df=1,28,	p=0.015),	whereas	no	difference	was	found	when	analyzing	DVR	values	calculated	either	using	2TCM	or	2TCM-1K	VT	(ST3).	No	statistically	significant	difference	between	patients	and	control	subjects	was	observed	for	plasma	AUC	(mean	=	6.84	x	104	(SD	=	2.7	x	104)	vs.	6.35	x	104	(2.2	x	104);	t=-0.56,	df=30,	p	=	0.58)	or	free	fraction	(8.2	(3.1)	vs.	9.0	(2.8);	t=-0.74,	df=30,	p	=	0.46).		
Correlations	between	[11C]PBR28	binding	and	behavioral	measures	In	patients,	there	was	no	significant	association	between	GM	VT	and	either	positive,	negative,	general	or	total	PANSS	scores,	CGI	or	duration	of	psychosis.	The	patients	performed	more	poorly	than	controls	in	all	the	cognitive	outcome	measures	(Table	1).	However,	there	were	no	significant	correlations	between	GM	VT	and	cognitive	performance	in	patients	after	correction	for	multiple	comparisons	(Table	3).		
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Discussion	The	results	of	the	present	study	are	novel	in	two	important	respects.	First,	this	is	to	our	knowledge	the	only	study	thus	far	to	investigate	TSPO	binding	in	drug-naïve	patients	with	psychosis.	The	finding	of	reduced	TSPO	levels	suggests	that	the	lack	of	increases,	or	even	trend-level	decreases	in	VT	reported	in	recent	studies	employing	novel	TSPO	radioligands14,15,17	is	not	explained	by	the	effects	of	antipsychotic	medication.		Second,	patients	had	a	mean	duration	of	illness	of	less	than	eight	months	which	is	significantly	shorter	than	in	previous	studies,	including	the	average	of	2.2	years	reported	in	a	recently	published	report	in	recent-onset	schizophrenia17.	Hence,	the	results	imply	that	there	is	no	TSPO	elevation	also	in	very	early	stages	of	disease.	Instead,	first	episode	psychosis	patients	may	even	be	characterized	by	having	decreased	glial	cell	activation.		TSPO	is	present	in	myeloid	and	astrocytic	cells	throughout	the	whole	brain,	also	at	physiological	conditions31,32.		Therefore,	quantification	of	radioligand	binding	to	TSPO	requires	a	metabolite	corrected	plasma	input	function	as	reference.	To	reduce	the	variability	induced	by	plasma	measurements,	relative	outcome	measures	of	binding	such	as	SUV	ratio	(SUVR)	or	DVR	have	been	suggested	instead	of	the	widely	used	VT	values33.	In	the	study	by	Bloomfield	et	al,	a	non-significant	reduction	of	around	10%	in	regional	VT	was	found	in	patients	and	ultra-high-risk	individuals,	whereas	VT	values	normalized	to	whole	brain	binding	showed	an	apparent	increase	in	both	groups14.	However,	the	normalization	approach	has	been	criticized34	.	Importantly,	the	WB	values	used	for	the	
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normalization	procedure	were	around	20%	lower	both	for	the	UHR	and	patient	groups	as	compared	to	controls,	a	difference	which	in	patients	appeared	to	be	driven	by	significant	decreases	in	white	matter.	Moreover,	DVR	values	were	obtained	using	WB	as	a	covariate	in	the	statistical	analysis	rather	than	dividing	the	region	of	interest	by	WB.	Since	a	high	degree	of	correlation	is	expected	between	WB	and	GM	regions,	this	method	may	reduce	variability	significantly,	resulting	in	increased	effect	sizes.	In	the	present	study,	the	observed	reduction	of	GM	TSPO	in	patients	did	not	remain	when	using	whole	brain–normalized	VT	(DVR,	ratio	method)	as	outcome	measure.	The	effect	of	using	DVR	instead	of	VT	was	thus	in	the	same	direction	as	for	Bloomfield	et	al.		The	lack	of	significant	increases	in	our	case	may	be	explained	by	the	statistical	DVR	procedure	as	well	as	the	use	of	different	WB	templates,	which	could	influence	WB	VT	values.	Finally,	we	observed	no	group	difference	in	the	metabolite-corrected	input	function	or	free	plasma	fraction	of	radioligand	in	our	data,	providing	support	for	the	validity	of	our	primary	outcome	measures35.			
	Evidence	for	a	heightened	immune	response	in	schizophrenia	patients	comes	primarily	from	biomolecular	studies,	showing	increases	in	pro-inflammatory	markers	both	in	long-term	illness	and	in	early	psychosis4–7.	With	regard	to	the	role	of	brain	immune	cells,	some	post-mortem	studies	have	shown	increased	levels	of	microglia	in	patients,	however	no	differences	or	even	decreases	have	also	been	reported36.	For	instance,	two	autoradiography	studies	assessing	TSPO	have	yielded	contrasting	results,	reporting	reductions	in	[3H]PK11195	and	increases	in	[3H]PBR28	binding	respectively37,38.	Whereas	initial	in	vivo	PET	studies	using	[11C]PK11195	in	small	samples	have	shown	increased	TSPO	
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binding	in	antipsychotic	drug	treated	schizophrenia	patients,	this	finding	has	not	been	replicated	using	more	recently	developed	TSPO	radioligands	with	higher	sensitivity.	Importantly,	preclinical	studies	combining	PET	with	post-mortem	immunohistochemistry	have	shown	a	close	correspondence	between	TSPO	levels	and	glial	cell	markers8,9.	Consequently,	although	the	high	variability	observed	in	human	TSPO	PET	studies	may	limit	the	sensitivity15,25,37,	a	plausible	interpretation	of	both	in	vitro	and	in	vivo	TSPO	studies	across	different	disease	stages	is	that	glial	up-regulation	is	not	a	robust	feature	of	schizophrenia.			 	Our	findings	of	reduced	TSPO	levels	in	drug-naive	patients	with	psychosis	is	congruent	with	the	numerically	lower	VT	values	reported	in	antipsychotic	drug	treated	patients	with	long-term	schizophrenia14,15,	as	well	as	the	trend-level	reductions	shown	in	recent-onset	patients17.	It	may	be	hypothesized	that	reduced	glial	activation	in	early	stage	psychosis	reflects	a	failure	of	the	immune	system	to	adapt	to	other	pathological	processes	associated	with	being	in	a	psychotic	state,	thus	promoting	the	development	of	the	disorder.	Importantly,	both	microglia	and	astrocytes	also	have	neuroprotective	and	pro-inflammatory	roles	in	the	brain39,	and	the	immune	hypothesis	in	schizophrenia	may	thus	be	thought	of	as	an	imbalance	rather	than	a	one-dimensional	activation.	A	limitation	is	that	TSPO	radioligands	cannot	differentiate	between	pro-	and	antiinflammatory	cell	phenotypes,	and	there	is	thus	a	need	for	immune	cell	markers	with	improved	functional	specificity.		This	view	is	corroborated	by	the	lack	of	significant	correlations	between	TSPO	VT	values	and	symptom	levels	or	cognitive	functioning	observed	in	our	study	as	well	as	in	previous	reports15,17.			
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In	the	present	study	the	decrease	in	TSPO	binding	was	more	prominent	in	the	group	of	HAB	individuals.	Although	the	lack	of	statistical	power	limits	the	conclusions	that	can	be	drawn	when	examining	the	genetic	groups	separately,	this	effect	may	partly	be	explained	by	the	higher	ratio	of	specific	to	non-displaceable	binding	in	HABs	compared	to	MABs31,40.	This	pattern	needs	confirmation	in	larger	samples	or	as	part	of	a	meta-analysis.		An	alternative	hypothesis	that	allows	for	reconciliation	of	the	lack	of	TSPO	elevation	at	least	with	genetic	and	epidemiological	data2,3	is	that	pro-inflammatory	microglial	activation	exerts	its	major	influence	preceding	the	onset	of	manifest	disease.	For	instance,	both	human	and	animal	research	has	suggested	a	link	between	immune	activation	and	excessive	synaptic	pruning41,42,	which	may	correspond	to	the	cortical	thinning	observed	already	in	early	stages	of	schizophrenia43.	Consequently,	although	all	patients	in	the	present	study	were	examined	during	their	first	psychotic	episode,	it	may	be	speculated	that	this	was	still	too	late	to	detect	a	hypothesized	increase	in	immune	cell	activation.			
Conclusion	In	this	study	we	found	a	decrease	in	TSPO	binding	in	antipsychotic-naïve	first	episode	psychosis	patients	compared	to	control	subjects,	indicating	lower	number	or	altered	function	of	immune	cells	in	brain	in	early	stage	schizophrenia.	Further	studies	combining	molecular	and	structural	brain	imaging	with	detailed	characterization	of	pro-	and	antiinflammatory	immune	markers	over	time	are	needed	to	clarify	the	role	of	the	immune	system	during	the	different	disease	stages	of	the	disorder.	
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Table 1. Demographic, radiochemical and clinical data for first episode psychosis patients and control subjects. 
Controls Patients chi-square t-value2 df Mann-whitney U value p-value
(N=16) (N=16)
Age 26.4 (8.4) 28.5 (8.4) 106.5 0.415
Gender Male/Female 7/9 11/5 2.032 1 0.154
Genotype HAB/MAB 9/7 8/8 0.125 1 0.723
Descriptive statistics BMI  21.9 (1.9) 22.9 (4.8) -0,722* 19.8 0.479
Education years 14.9 (2.2) 13.6 (3.3) 1.278 25 0.213
Nicotine-user Yes/No 0/16 2/14 NA3
PET measures Injected mass tracer (µg) 0.68 (0.57) 0.66 (0.32) 0.166 30 0.870
Specific radioactivity (GBq/µmol) 313.8 (213.4) 276.4 (170.8) 120.5 0.777
Injected radioactivity (MBq) 403.9 (52.5) 402.1 (69.5) 0.083 30 0.934
Duration of illness (months)1 7.9 (9.6)
PANSS1 Positive 20.3 (4.9)
Negative 18.1 (7.0)
General 39.1 (10.8)
Total 77.4 (18.3)
Level of functioning1 CGI 4.6 (1.2)
(N=16) (N=15)
Cognitive measurements
MATRICS TMT 22.6 (4.6) 35.5 (14.4) 36 8.65*10-4
HVLT-R 28.4 (2.3) 21.2 (5.8) 26 1.65*10-4
WMS-III-SS 19.0 (2.2) 14.8 (3.4) 32.5 4.90*10-4
BVMT-R 29.0 (5.4) 19.1 (6.6) 4.581 29 8.10*10-5
Fluency 25.6 (6.7) 18.8 (4.2) 3.368 29 0.002
(N=14)
CPT-IP 2.9 (0.4) 2.0 (0.4) 5.316 28 1.20*10-5
(N=15) (N=13)
WCST PctErrors 14.6 (7.5) 33.3 (18.2) 27.5 0.00123
CatCompl 5.9 (0.3) 4.5 (2.1) 64 0.0315
Averages and standard deviations are reported as Mean (SD). PANSS=Positive and Negative Symptom Scale in Schizophrenia; CGI=Clinical Global Impression (1-6); WCST=Wisconsin 
Card Sorting Test; TMT=Trail Making Test: Part A; HVLT-R=Hopkins Verbal Learning Test - Revised; WMS-III-SS=Wechsler Memory Scale III: Spatial Span; BVMT-R=Brief Visuospatial 
Memory Test Revised; CPT-IP=Contiunous Performance Test-Identical Pairs; WCST=Wisconsin Card Sortin Test; PctErrors=Percent errors; CatCompl=Categories completed. *Equality of 
variance not assumed, Welch's Independent sample t-test was performed. 1. Ratings only exist for patient group 2. In the case of equality of variance Welch's t-test was performed. 3. 
Expected cell counts too low to perform a chi-square test.
Region Mean SD Mean SD t-value p-value
Whole Brain 1230.7 130.8 1256.0 126.2 -0.6 0.582
Grey Matter 738.7 61.7 739.1 71.8 -0.015 0.988
Frontal Cortex 153.7 12.3 156.1 18.5 -0.431 0.670
Temporal Cortex 110.5 7.5 111.8 13.1 -0.357 0.723
Hippocampus 8.8 0.8 8.7 0.7 0.255 0.801
SD=Standard deviation. All volumes expressed in cm3. p-value as determined using an 
independent sample t-test.  
Table 2. Comparison of measured ROI volumes between first episode patients with psychosis 
and healthy control subjects. 
Controls (N=16) Patients (N=16)
r df p-value
Duration of Illness (months)1 0.035 12 0.91
PANSS1 Positive 0.45 12 0.11
Negative 0.10 12 0.73
General 0.29 12 0.31
Total 0.35 12 0.22
Level of functioning1 CGI 0.41 12 0.14
Cognitive measures 2,3
MATRICS (N=15) TMT -0.41 10 0.19
HVLT_R 0.70 10 0.012
WMS_III_SS -0.082 10 0.80
BVMT_R 0.21 10 0.52
Fluency 0.016 10 0.96
(N=14) CPT_IP -0.15 9 0.66
WCST (N=13) PctErrors -0.049 8 0.89
CatCompl 0.016 8 0.97
r=partial correlation coefficient. 1. Controlling for TSPO genotype and gender. 2. Controlling 
for TSPO genotype, gender and age. 3. Bonferroni corrected alpha-value=0.00625.
Table 3. Partial correlations between GM VT and clinical and cognitive variables in patients 
with first episode psychosis.
